The concentrations of plasma tau phosphorylated at three particular sites (pTau181, pTau217, or pTau231) are significantly increased in individuals with clinically diagnosed AD compared with both cognitively unimpaired controls and individuals with non‐AD dementias.94 The gene discussed is MAPT; the disease is dementia.